NCT04730635View on ClinicalTrials.gov

Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 23, 2021

Primary Completion Date

January 20, 2023

Study Completion Date

February 6, 2023

Conditions
Alzheimer's DiseaseMild Cognitive Impairment
Interventions
DRUG

Donepezil

Donepezil 5 mg capsules for a total daily dose of up to 10 mg QD, orally, for Days 1-56.

DRUG

Placebo

Dose matched placebo capsule QD, orally for Days 1-56.

Trial Locations (10)

3084

Austin Health ( Site 0030), Heidelberg

5000

Royal Adelaide Hospital-CALHN Memory Trials ( Site 0031), Adelaide

30030

iResearch Atlanta ( Site 0005), Decatur

31405

iResearch Savannah ( Site 0023), Savannah

32159

Charter Research - Lady Lake ( Site 0025), Lady Lake

33009

Velocity Clinical Research, Hallandale Beach ( Site 0013), Hallandale

44122

Insight Clinical Trials ( Site 0020), Beachwood

70808

Pennington Biomedical Research Center ( Site 0006), Baton Rouge

76104

North Texas Clinical Trials - Fort Worth - West Rosedale ( Site 0022), Fort Worth

90806

Collaborative Neuroscience Network ( Site 0010), Long Beach

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04730635 - Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413) | Biotech Hunter | Biotech Hunter